Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

SELL
$10.99 - $44.21 $70,039 - $281,750
-6,373 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$27.95 - $45.04 $24,260 - $39,094
868 Added 15.77%
6,373 $234,000
Q4 2017

Feb 14, 2018

BUY
$35.44 - $63.76 $195,097 - $350,998
5,505
5,505 $206,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $678M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Holocene Advisors, LP Portfolio

Follow Holocene Advisors, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

News

Stay updated on Holocene Advisors, LP with notifications on news.